tiprankstipranks
Immunic (IMUX)
NASDAQ:IMUX
Holding IMUX?
Track your performance easily

Immunic (IMUX) Income Statement

1,260 Followers

Immunic Income Statement

Last quarter (Q3 2024), Immunic's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Immunic's net income was $-24.37M. See Immunic’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 95.80M$ 99.22M$ 86.52M$ 91.67M$ 48.97M$ 37.03M
Operating Income
$ -95.80M$ -99.22M$ -119.49M$ -91.67M$ -48.97M$ -37.03M
Net Non Operating Interest Income Expense
$ 3.50M$ 3.08M$ 1.04M$ 66.00K$ 58.00K$ 107.00K
Other Income Expense
$ -192.00K$ 2.54M$ -34.93M$ 1.35M$ -4.90M$ -1.99M
Pretax Income
$ -92.11M$ -93.61M$ -120.41M$ -58.45M$ -44.02M$ -34.93M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -96.90M$ -93.61M$ -120.41M$ -92.94M$ -44.02M$ -34.93M
Basic EPS
$ -1.23$ -2.11$ -3.78$ -3.93$ -2.81-
Diluted EPS
$ -1.23$ -2.11$ -3.78$ -3.93$ -2.81$ -4.52
Basic Average Shares
$ 344.45M$ 44.32M$ 31.82M$ 23.65M$ 15.66M$ 7.72M
Diluted Average Shares
$ 344.45M$ 44.32M$ 31.82M$ 23.65M$ 15.66M$ 7.72M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 95.80M$ 99.22M$ 86.52M$ 91.67M$ 48.97M$ 37.03M
Net Income From Continuing And Discontinued Operation
$ -96.90M$ -93.61M$ -120.41M$ -92.94M$ -44.02M$ -34.93M
Normalized Income
$ -86.87M$ -73.95M-$ -46.17M--
Interest Expense
------
EBIT
$ -93.92M$ -99.22M$ -86.52M$ -91.67M$ -48.97M$ -34.93M
EBITDA
$ -93.80M$ -99.11M$ -86.44M$ -91.58M$ -48.93M$ -34.88M
Currency in USD

Immunic Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis